Boston Scientific Adjusts To New PFA Landscape As Medtronic, J&J And Abbott Take Market Share

 
• By Shubham Singh
  
CFO Jonathan Monson said the top capital allocation priority remains strategic tuck-in M&A followed by share repurchases.
For the full year of 2026, the company reduced its organic growth guidance to 6.5% to 8and guided to second-quarter organic growth of 5% to 7%. Picture Courtesy: Shutterstock

More from Earnings

More from Business